This inventor holds 1 USPTO granted patent. Top assignees: Arch Development Corporation, The Penn State Research Foundation, The United States of America as Represented by the Department of Health. Active years: 1997.
Company Filing History:
1 out of 349 
1 out of 1,338 
1 out of 1,217 
Years Active: 1997
Title: Mark G McDougall: Innovator in Pharmaceutical Compositions
Introduction
Mark G McDougall is a notable inventor based in Cleveland, OH (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific DNA repair mechanisms in tumor cells. His innovative work has the potential to enhance cancer treatment protocols.
Latest Patents
Mark G McDougall holds a patent for O.sup.6 -substituted guanine compositions and methods for depleting O.sup.6. This patent describes novel O.sup.6 -substituted guanine compounds and pharmaceutical compositions that are effective in reducing O.sup.6 -alkylguanine-DNA alkyltransferase (AGT). The compounds are particularly useful for treating tumors and, when combined with anti-neoplastic alkylating agents, can enhance the chemotherapeutic treatment of tumor cells in a host. He has 1 patent to his name.
Career Highlights
Throughout his career, Mark has worked with various organizations that focus on research and development in the pharmaceutical sector. Notably, he has been associated with the Penn State Research Foundation and Arch Development Corporation. His work in these institutions has contributed to advancements in cancer treatment methodologies.
Collaborations
Mark G McDougall has collaborated with several professionals in his field, including Robert C Moschel and Mi-Young Chae. These collaborations have fostered a productive environment for innovation and research in pharmaceutical sciences.
Conclusion
Mark G McDougall's contributions to the field of pharmaceuticals, particularly through his patent on O.sup.6 -substituted guanine compositions, highlight his role as an innovator in cancer treatment. His work continues to influence the development of effective therapies for tumor management.